Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurora Spine Corp V.ASG

Alternate Symbol(s):  ASAPF

Aurora Spine Corporation is a designer and manufacturer of medical devices. The Company is engaged in the development and distribution of minimally invasive, interspinous fusion systems and devices. It offers a range of devices specifically designed to address cervical spine conditions and restore optimal functionality. Its Cervical product line includes apollo, Discovery, and DEXA-C. The apollo Anterior Cervical Plate system is comprised of cervical plates and bone screws constructed of titanium alloy as described by ASTM F136. Discovery is its Spine's invasive cervical interbody fusion system. The DEXA-C is crafted to mimic the lattice structure of cancellous bone in humans while maintaining a comparable modulus of elasticity. The Company has established a physician training program through national and regional cadaver labs.


TSXV:ASG - Post by User

Post by Topdog2022on May 04, 2022 11:49am
105 Views
Post# 34655211

From conference call

From conference call

-Aurora has grown from having 40 doctors selling Aurora's pain division product/devices to now 60 as of the call.     
 

-Aurora is training another 300 doctors this year with an adoption success rate of 20% this could lead to seeing over 100 doctors by year end.

-Currently the average doctor returns $10k/month.  Management hopes to increase the organic growth.

-DEXA-C is now selling in a controlled rollout.  A larger push will be made in Q1.

-Silo-TFX is still awaiting FDA approval.  Aurora has plans to make a big sales push once approvals are given.

-Break even is approx $1.2m/month now.

-Q1 will see sequentially higher sales with results out at the end of May.

<< Previous
Bullboard Posts
Next >>